Diaceutics (DXRX)

Sector:

Health Care

Index:

FTSE AIM All-Share

102.71p
   
  • Change Today:
    -1.29p
  • 52 Week High: 109.00
  • 52 Week Low: 80.50
  • Currency: UK Pounds
  • Shares Issued: 84.68m
  • Volume: 33,678
  • Market Cap: £86.97m
  • RiskGrade: 196

Diaceutics Overview

Diaceutics is a data analytics and implementation services company which services the global pharmaceutical industry. It has established a suite of data-driven products and implementation services powered by the data held in its proprietary database. Its products and services are focused on optimising its clients’ strategies for the development and launch of precision medicines and specifically, the diagnostic testing required to guide selection of such medicines. The Group currently provides services to 20 of the 30 largest global pharmaceutical companies.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn 2.9% n/a
ROCE 2.0%  
Latest F'cast
P/E 120.9 n/a
PEG 4.3 n/a
Pr/Revenue 4.5 n/a
Pr/Book 2.1  
Latest F'cast
Revenue 39.9% n/a
PBT 22.1% n/a
EPS 28.4% n/a
DPS n/a n/a

Diaceutics Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-18 10.37 0.88 1.86p n/a n/a n/a n/a 0.0%
31-Dec-19 13.44 0.50 2.46p 41.5 1.3 +32% n/a 0.0%
31-Dec-20 12.70 (0.68) 0.74p 180.4 n/a -70% n/a 0.0%
31-Dec-21 13.94 0.46 0.67p 152.2 n/a -10% n/a 0.0%
31-Dec-22 19.50 0.56 0.86p 87.8 3.1 +28% n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Diaceutics Company Announcements

Director/PDMR Shareholding 07-Mar-2024 07:00 RNS
PDMR Shareholding / SIP and TVR 01-Mar-2024 09:00 RNS
Expanded lab network and data capabilities 27-Feb-2024 07:00 RNS

Latest Diaceutics Director Deals

Traded Action Notifier PriceAmountValue
06-Mar-24 Buy Graham Paterson 98.50p 33,564 £33,060.54
30-Jan-24 Transfer From Nick Roberts 0.000p 152 £0.00
30-Jan-24 Buy Nick Roberts 0.99p 152 £1.50

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Diaceutics Market Data

Currency UK Pounds
Share Price 102.71p
Change Today -1.29p
% Change -1.24 %
52 Week High 109.00
52 Week Low 80.50
Volume 33,678
Shares Issued 84.68m
Market Cap £86.97m
RiskGrade 196

Diaceutics Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
90.45% below the market average90.45% below the market average90.45% below the market average90.45% below the market average90.45% below the market average
80% below the sector average80% below the sector average80% below the sector average80% below the sector average80% below the sector average
Price Trend
10.97% above the market average10.97% above the market average10.97% above the market average10.97% above the market average10.97% above the market average
35.14% above the sector average35.14% above the sector average35.14% above the sector average35.14% above the sector average35.14% above the sector average
Income Not Available
Growth
2.41% above the market average2.41% above the market average2.41% above the market average2.41% above the market average2.41% above the market average
5.56% above the sector average5.56% above the sector average5.56% above the sector average5.56% above the sector average5.56% above the sector average

Diaceutics Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
08:23 12,500 @ 104.65p
08:23 12,500 @ 104.00p
08:45 4,678 @ 104.60p
08:43 4,000 @ 104.65p

Diaceutics Key Personnel

CEO Ryan Gerard Keeling
CFO Nick Roberts

Top of Page